Recent translational research into targeted therapy for liposarcoma.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Liposarcomas (LPS) are common soft tissue sarcomas arising from adipocytes.
• Current treatments for LPS include surgery and radiation, but chemotherapy efficacy for advanced disease is debated.

Purpose of the Study:

• To review recent translational research and clinical trials of novel therapies for liposarcomas.
• To identify potential therapeutic targets based on genetic and molecular aberrations in LPS.

Main Methods:

• Review of translational research and clinical trials.
• Analysis of genetic and molecular aberrations implicated in LPS pathogenesis.
• Evaluation of targeted therapies including tyrosine kinase inhibitors and pathway modulators.

Main Results:

• Identified key genetic aberrations (e.g., 12q13-15 amplicon, MDM2, CDK4 amplification; CTNNB1, CDH1 mutations; FUS-DDIT3/EWSR1-DDIT3 fusions) as therapeutic targets.
• Highlighted the efficacy of tyrosine kinase inhibitors (targeting MET, AXL, IGF1R, EGFR, VEGFR2, PDGFR-β, Aurora kinase) in specific LPS subtypes.
• Noted the therapeutic potential of targeting PI3K/Akt pathway, C/EBP-α/PPAR-γ deregulation, and CRT/CD47 interaction.

Conclusions:

• Novel therapeutic strategies targeting specific molecular and genetic alterations in liposarcomas are emerging.
• These targeted therapies show promise in supplementing existing treatment modalities for unresectable or metastatic liposarcomas.